Authors
Latest:
Neoadjuvant chemoimmunotherapy combo shows promise in UTUCThe phase 2 study explored the combination of the PD-1 inhibitor toripalimab and chemotherapy as neoadjuvant treatment for patients with upper tract urothelial carcinoma.
Latest:
Register Today! UH Urology Institute’s Fall SymposiumsUniversity Hospitals Urology Institute is excited to announce that this coming fall, the department is hosting 2 educational courses in cutting-edge urologic specialties: female sexual health and gender care.
Latest:
Robert Svatek, MD, discusses the design of the PIVOT-006 trial“The trial is meant to define or test this agent in this population for which currently there's not an established standard of care,” says Robert Svatek, MD.
Latest:
Desai Sethi Urology Institute shares inaugural Annual ReportThe report, titled "TRANSFORMATION: From an academic department to a leading Institute," highlights DSUI's transformation from a department into a multidisciplinary institute.
Latest:
Allina Health Cancer Institute 2022 Symposium reimagines cancer careThe symposium brings together clinicians devoted to solving the disease of cancer and the many challenges associated with it.
Latest:
The role of surgery continues to evolve in seminoma"RPLND is an attractive option for those who prefer to avoid chemotherapy," write Jiping Zeng, MD; Timothy A. Masterson, MD; and Clint Cary, MD, MPH, MBA.
Latest:
Tobias Nordström, MD, on the evolving landscape of prostate cancer screening“Another aspect is how to make this more and more complex diagnostic chain for prostate cancer work in practice, because we now have so [many] more tools than we had a decade ago,” says Tobias Nordström, MD, PhD.
Latest:
Nima Sharifi, MD, on the link between HSD3B1 and OS in prostate cancer“We hypothesized based on prior work that specifically men with low-volume disease, if they inherit this hyperactive form of HSD3B1, they'll have shorter overall survival. It turns out that that's true,” says Nima Sharifi, MD.
Latest:
Letter: Declassifying Gleason 6 as a cancer would do more harm than good"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
Latest:
Ralph Miller, MD, on the state of HIFU in prostate cancer"Most of the published data about HIFU tended to be with relatively short-term follow-up," says Ralph J. Miller Jr, MD.
Latest:
Abiraterone-based triplet boosts survival in de novo mCSPCFindings from the PEACE-1 trial published in the Lancet showed that adding abiraterone acetate and prednisone to androgen-deprivation therapy and docetaxel improved overall survival in patients with de novo metastatic castration-sensitive prostate cancer.
Latest:
Episode 3 Video: Treatment Strategies to Tackle NMIBC HeterogeneityPanelists examine disease heterogeneity in NMIBC and discuss a balanced treatment approach that prioritizes patient quality of life and surgery effectiveness.
Latest:
The evolving role of microRNAs in testicular cancer management"This brief review captures the evolving role of miRNAs, focusing on their clinical relevance and implications as well as future directions for more effective targeted therapeutic interventions," write the authors.
Latest:
Smaller medical practices increasingly targeted for cyber attacksPatient data is so valuable — and smaller providers are more vulnerable — that hackers are increasingly targeting physician groups.
Latest:
The aging surgeon: A geriatrician's perspective"We all need to revisit meaningful methods for ongoing assurance of competency specific to our fields of medicine and surgery across the physician career span," writes Hal H. Atkinson, MD, MS.
Latest:
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBCPanelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Latest:
Novel intravesical drug delivery systems explored in bladder cancer"TAR-200 is a sort of a pretzel device. It's a novel drug delivery mechanism that's placed inside the bladder for sustained release of gemcitabine," explains Siamak Daneshmand, MD.
Latest:
Expert advice on improving interactions with difficult patients“Patients will never change, and demanding family members will never change. The solution to the problem is to manage the way we think about them,” writes Joan Naidorf, DO.
Latest:
Christina Ching, MD, on overcoming barriers to follow-up after pediatric stone surgery“We might need to do a better job in general about education of the importance of follow-up,” says Christina B. Ching, MD.
Latest:
BCG-unresponsive NMIBC: Current evidence and optionsMultiple investigational agents have been developed and are being studied.
Latest:
Sexual QOL improved at 12 months following AUS placement"I think this is a very important trial, just to bring some importance about patients' worries about being sexually active with urinary incontinence," says LeRoy Jones, MD.
Latest:
Malpractice Consult: What to know about closing arguments"All the components of the trial are designed to try to ensure that when the jurors depart for the deliberation room, they are inclined to find for the attorney’s side in the case," writes Austin Richards, Esq.
Latest:
Future Directions for the Management of Advanced Prostate CancerBobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.
Latest:
Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
Latest:
Francesca Jackson-Spence, MBChB, details the ongoing SAMETA trial in papillary renal cancer“The primary end point is progression-free survival, and the secondary end points are overall survival, objective response rates, duration of response, and safety.”
Latest:
Financial toxicity is a growing concern in urologic oncology"Clinicians have opportunities to reduce patient subjective and objective financial burden if they continue to self-educate and communicate with patients and consider [financial toxicitiy] an adverse effect of treatment," write Alexandria A. Spellman, MD, MS, and Deborah R. Kaye, MD, MS.
Latest:
Episode 2 Video: Managing Overactive Bladder: From Dual Diagnoses to Geriatric ChallengesPanelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
Latest:
Management of BCG-unresponsive NMIBC"An alternative off-label option for patients with BCG-unresponsive NMIBC is sequential intravesical gemcitabine and docetaxel (Gem/Doce)," write Rachel Passarelli, MD, and Vignesh T. Packiam, MD.
